The call emphasized strong operational momentum and a clear turnaround to sustained profitability, with multiple positive financial metrics (revenue and EBITDA growth, margin expansion, bed additions, improved leverage, cash generation and a deferred tax asset). Operational and strategic initiatives (hub-and-spoke, new Burnaby hub, clinical programs and government engagement) support growth prospects. Key risks highlighted were timing/regulatory uncertainty around onboarding new beds, an early-stage M&A pipeline, and some near-term cash balance decline. On balance the positive achievements and improved financial profile materially outweigh the identified risks.

Company Guidance

Management's forward guidance and targets included a 2026 organic bed growth goal of 6,000–8,000 net new beds (which management said could help push adjusted EBITDA into double-digit margins), plans to add two more hub facilities within ~24 months, continued capital allocation to a quarterly dividend and renewed NCIB (Q4 dividend paid was $1.3M), discretionary annual maintenance/expansion capex of roughly $8–$10M, opportunistic M&A as warranted, and close monitoring of semaglutide (expected by management to potentially go generic late in the year); they also highlighted the company’s strong balance-sheet position (cash $13.9M, net debt $27.1M, net debt/adjusted EBITDA ~0.8x, and a ~24% Y/Y reduction in net debt) as enabling this growth plan.

Quarterly Revenue Growth

Q4 revenue of $96.1M versus $92.2M in Q4 2024, an increase of approximately 4.2%, driven primarily by higher average beds serviced.

Adjusted EBITDA and Margin Expansion

Q4 adjusted EBITDA rose to $8.8M from $7.6M year-over-year, an increase of ~15.8%, and adjusted EBITDA margin improved to 9.2% from 8.2% (up ~100 basis points), reflecting onboarding of new beds and cost/efficiency initiatives.

Full-Year Profitability Milestone

Fiscal 2025 revenue was $370.2M with adjusted EBITDA of $32.9M and adjusted EBITDA margin of 8.9%. Management reported 2025 as the first full year of positive net income ($3.3M) for the company.

Net Income Improvement (Quarter)

Q4 net income of $1.0M compared to a net loss of $2.2M in Q4 2024 — a material swing to profitability in the quarter driven by higher volumes, cost savings and lower finance costs.

Bed Growth and Operational Scale

Average beds serviced increased to 92,250 in Q4 from 87,658 in Q4 2024 (+4,592 beds, ~5.2% increase). The company added over 4,500 new beds in 2025 and targets 6,000–8,000 net new organic beds for the current year, supporting incremental accretion due to low additional labor needs.

Improved Balance Sheet and Leverage

Net debt fell to $27.1M at quarter end (from $28.8M in prior quarter) and improved ~24% year-over-year in reported commentary. Net debt to adjusted EBITDA improved to 0.8x from 0.9x quarter-over-quarter, signaling low leverage.

Operating Cash Generation

Cash from operations in Q4 was $9.6M versus $8.4M in Q4 2024, an increase of ~14.3%, supporting dividend payments and debt repayments.

Capital Allocation & Shareholder Returns

Company initiated a quarterly dividend, paid $1.3M in the quarter, and renewed a normal course issuer bid (NCIB), while maintaining $8M–$10M annualized capital expenditure guidance.

Strategic and Clinical Achievements

Operational milestones include full transition of BC Lower Mainland beds to a new Burnaby hub, Oakville hub expansion (hub-and-spoke pilot), hosting government stakeholders, administering >40,000 flu shots in Q4, and publication of a diabetes management study co-led by CareRx pharmacists.

Deferred Tax Asset Recognition

Management recognized a deferred tax asset (~$23M on the balance sheet) after achieving sustained profitability and forecasting future taxable income, enabling utilization of non-capital losses.

CareRx (TSE:CRRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:CRRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 13, 2026	2026 (Q1)	0.05 / -	0	―	―	―
Mar 04, 2026	2025 (Q4)	0.03 / 0.37	-0.04	1025.00% (+0.41)		―
Nov 03, 2025	2025 (Q3)	0.03 / 0.02	-0.01	300.00% (+0.03)	―	―
Jul 30, 2025	2025 (Q2)	0.01 / 0.01	-0.02	150.00% (+0.03)	―	―
May 07, 2025	2025 (Q1)	>-0.01 / 0.00	-0.01	―	―	―
Mar 05, 2025	2024 (Q4)	0.02 / -0.04	-0.06	33.33% (+0.02)	―	―
Nov 08, 2024	2024 (Q3)	0.01 / -0.01	-0.02	50.00% (+0.01)	―	―
Aug 08, 2024	2024 (Q2)	<0.01 / -0.02	0.03	-166.67% (-0.05)	―	―
May 10, 2024	2024 (Q1)	-0.01 / -0.01	-0.04	75.00% (+0.03)	―	―
Mar 07, 2024	2023 (Q4)	-0.02 / -0.06	-0.1	40.00% (+0.04)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:CRRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 04, 2026	C$3.83	C$3.82	-0.26%
Nov 03, 2025	C$3.48	C$3.63	+4.31%
Jul 30, 2025	C$2.81	C$2.81	0.00%
May 07, 2025	C$2.60	C$2.55	-1.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CareRx (TSE:CRRX) report earnings?

CareRx (TSE:CRRX) is schdueled to report earning on May 13, 2026, After Close (Confirmed).

What is CareRx (TSE:CRRX) earnings time?

CareRx (TSE:CRRX) earnings time is at May 13, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:CRRX EPS forecast?

TSE:CRRX EPS forecast for the fiscal quarter 2026 (Q1) is 0.05.